Be the first person to write a business review for Dow Pharmaceutical Sciences

Dyadic International, Inc. (Dyadic) is an early-stage biotechnology company. The Company has operations in the United States, the Netherlands and Poland. Dyadic uses its technologies to conduct research and development (R&D) and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme, and biopharmaceutical industries. The Company derives all of its revenues from the licensing of its technologies and the sale of its enzymes. The Company is a holding company that holds all of Dyadic International (USA), Inc. (Dyadic-Florida). Dyadic-Florida owns all of Geneva Investment Holdings Limited, Dyadic Nederland BV, and Dyadic International Sp. z o.o. Dyadic’s R&D activities focus on its fungal strains and associated technologies. In particular, Dyadic uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes.

Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts. Dyax Corp. (Dyax) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company uses the drug discovery technology, known as phage display, to identify antibody, small protein and peptide compounds for clinical development. The Company’s product DX-88 (ecallantide), is in late stage clinical trial development in two separate indications. In addition to DX-88, the phage display technology has allowed Dyax to develop a substantial pipeline of drug candidates. In June 2008, the Company completed a second phase three study, known as EDEMA4.

Elan Pharmaceuticals is part of the the brains behind the brawn of drugmaker Elan Corporation. The US-based subsidiary provides research and discovery services, such as the identification and development of new drug candidates, to its Irish parent, which specializes in treatments for neurological and autoimmune diseases, as well as severe pain and infectious disease medications. The company investigates possible treatments for diseases such as Alzheimer's disease, Parkinson's disease, and multiple myeloma. The subsidiary also handles marketing of Elan's approved products in the US, including multiple sclerosis/Crohn's disease treatment Tysabri and chronic pain medication Prialt.

Elusys Therapeutics is recruiting antibodies in its anti-terrorism campaign. Elusys Therapeutics company develops antibody therapies for a variety of targets, including anthrax. Its lead product Anthim has shown to be effective in combatting infections caused by anthrax up to 48 hours after exposure. When administered prior to exposure, the drug has proven to be 100% effective in preventing infections. Another drug candidate, Staph A Heteropolymer, targets staphylococcus infections, which have become increasingly prevalent and resistent to treatment. Other Elusys products target non-Hodgkin's lymphomas, lupus, and deep vein thrombosis.

EMD Serono develops a potpourri of prescription pharmaceuticals used for the treatment of neurological, metabolic, and fertility disorders and diseases such as multiple sclerosis (MS), lupus, and HIV. The Massachusetts-based company conducts research and development programs in the US and markets products that include Gonal-f, Luveris, Ovidrel, Rebif, and Zorbtive in the US and Canada. The company has manufacturing and marketing agreements with other pharmaceutical firms, including Pfizer (MS) and CuraScript (fertility). EMD Serono is the North American operating subsidiary of Merck Serono S.A..

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.